Thanks to advances in RNA technology, we can now engineer medicines that produce therapeutic proteins within targeted cells and tissues. Our RNA platform reprograms immune cells directly inside the body, in vivo, enabling precise and flexible treatment at the source of disease — without the complexity of ex vivo cell therapies.
To treat or prevent disease effectively, each RNA therapy must match the biological demands of the disease, including what protein is needed, how long it should act, and where it needs to go.
We design each therapy across three key dimensions:
By tuning these three dimensions, we aim to create immune-modulating therapies that can be administered in standard care settings, expanding the options for treating complex conditions with long-lasting benefits – all without the burden of cell harvesting, lab manipulation, or inpatient regimens.
Together with our team’s deep expertise, we draw from a purpose-built, integrated platform of established and emerging RNA technologies, selecting the right tools to engineer programmable RNA medicines tailored to each disease.
Our proprietary platform combines RNA design, delivery systems, data science, and automation to advance therapies with precision, durability, and flexibility.
This links to an external website.